MOLN — MOLECULAR PARTNERS AG

—
Nasdaq · Health Care · Biotechnology · CIK 1745114 ·
Last close
$2.86
Market Cap
$109.55M
52W High
$5.36
52W Low
$2.63
ADV30
1,986
Next earnings
2026-08-25

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -12,061,000 -11,708,000 64,515,000 57,493,000 13,853,000
Jun 2026 0 — -13,591,000 -13,561,000 75,698,000 67,930,000 17,154,000
Mar 2026 0 — -13,443,000 -13,144,000 87,658,000 64,251,000 19,206,000
Dec 2025 0 — -12,667,000 -12,649,000 102,107,000 82,653,000 21,773,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-46,691,000
Investing CF
$22,454,000
Financing CF
$-1,103,000
CapEx
$-714,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.34
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-344,072,000
Inventory
—
Receivables
$1,569,000
ST Investments
$0
EBIT TTM
$-51,034,000
Pretax Income TTM
$-51,058,000
Interest Exp TTM
$24,000
Analysts
5

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -55,436,000 -61,651,000 102,107,000 21,773,000 80,334,000 -51,257,000
Dec 2024 4,970,000 -61,217,000 -54,043,000 158,528,000 16,891,000 141,637,000 -59,248,000
Dec 2023 7,038,000 -61,108,000 -61,984,000 198,352,000 21,923,000 176,429,000 -59,005,000
Dec 2022 189,556,000 116,613,000 117,853,000 262,258,000 27,092,000 235,166,000 118,566,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.17

Peers — same industry

TickerNameMarket CapLastDaily %
CMPX Compass Therapeutics, Inc. $109.26M $0.61 —
LENZ LENZ Therapeutics, Inc. $109.97M $3.50 —
CRDL Cardiol Therapeutics Inc. $113.53M $0.97 —
ENGN enGene Therapeutics Inc. $115.27M $1.72 —
ZURA Zura Bio Ltd $99.70M $1.03 —

News headlines (Yahoo Finance, 1h cache)

Molecular Partners to Present at Inaugural UBS Global Biopharma Conference
2026-11-13 06:00 · Yahoo
Molecular Partners Presents New Preclinical Data for Next-Generation T Cell Engager MP0632 at SITC 2026
2026-11-06 06:00 · Yahoo
Molecular Partners to Present on DLL3-Targeting Radio-DARPin MP0712 at 2026 SNMMI Theranostics Conference and NACLC 2026
2026-11-05 06:00 · Yahoo
After Plunging 18.3% in 4 Weeks, Here's Why the Trend Might Reverse for Molecular Partners AG Sponsored ADR (MOLN)
2026-11-04 13:35 · Yahoo
Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy
2026-10-29 06:00 · Yahoo
Molecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70
2026-10-22 05:00 · Yahoo
Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study
2026-08-25 05:00 · Yahoo
Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma
2026-07-16 05:00 · Yahoo
Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference
2026-07-15 05:00 · Yahoo
Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics
2026-07-06 05:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.